GlucoTrack, Inc. (NASDAQ:GCTK) Director Drew Sycoff Purchases 182,540 Shares of Stock

GlucoTrack, Inc. (NASDAQ:GCTK) Director Drew Sycoff acquired 182,540 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were purchased at an average price of $1.26 per share, with a total value of $230,000.40. Following the completion of the acquisition, the director now owns 2,951,258 shares of the company’s stock, valued at approximately $3,718,585.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

GlucoTrack Price Performance

NASDAQ:GCTK opened at $0.48 on Thursday. The company has a current ratio of 3.22, a quick ratio of 3.22 and a debt-to-equity ratio of 0.06. GlucoTrack, Inc. has a 52-week low of $0.13 and a 52-week high of $1.00. The stock has a 50-day simple moving average of $0.38 and a 200 day simple moving average of $0.28.

GlucoTrack (NASDAQ:GCTK) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.10) earnings per share (EPS) for the quarter.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.